دورية
Safety of concurrent adjuvant radiotherapy and chemotherapy for locally advanced soft tissue sarcoma
| العنوان: | Safety of concurrent adjuvant radiotherapy and chemotherapy for locally advanced soft tissue sarcoma |
|---|---|
| المؤلفون: | Greto, Daniela, Loi, Mauro, Saieva, Calogero, Muntoni, Cristina, Delli Paoli, Camilla, Becherini, Carlotta, Ciabatti, Cinzia, Perna, Marco, Campanacci, Domenico, Terziani, Francesca, Beltrami, Giovanni, Scoccianti, Guido, Bonomo, Pierluigi, Meattini, Icro, Desideri, Isacco, Simontacchi, Gabriele, Mangoni, Monica, Livi, Lorenzo |
| المصدر: | Tumori Journal; October 2018, Vol. 104 Issue: 5 p322-329, 8p |
| مستخلص: | Introduction: This retrospective study analyzes the safety and feasibility of concurrent chemoradiotherapy (CRT) in adjuvant treatment of soft tissue sarcoma (STS).Methods: A total of 158 patients with STS were retrospectively analyzed. Anthracycline-based computed tomography was performed in high-risk patients. Acute radiotherapy toxicity and chemotherapy-related toxicity were assessed according to the Common Terminology Criteria for Adverse Events 4.0; late radiotherapy toxicity was recorded according to Radiation Therapy Oncology Group/European Organization for Research and Treatment of Cancer criteria.Results: Fifty-four (34.2%) patients received CRT. Mean follow up was 5.4 years (range .2–21.1 years). Local DFS–recurrence-free survival, distant DFS–relapse-free survival, and overall survival were 79.1%, 76.4%, and 64.6%, respectively, at last follow-up. Leukopenia occurred in 11.4% of patients. Skin acute toxicity developed in 60.1% of patients and determined interruption of radiotherapy treatment in 19 (12%) patients. Nineteen patients (12%) experienced moderate fibrosis (grade 2). Mild and moderate joint stiffness was recorded in 16 (10.1%) patients. Size ≥5 cm was the only predictor of local recurrence at multivariate analysis (hazard ratio [HR] 9.65, 95% confidence interval [CI] 1.28–72.83, p= .028). Age and stage resulted as independent distant relapse predictors (HR 4.77, 95% CI 1.81–12.58, p= .002 and HR 4.83, CI 1.41–16.57, p= .012, respectively). At Cox regression univariate analysis, Karnofsky Performance Status, size, and stage were significant survival predictors (HR 2.23, 95% CI 1.02–4.87, p= .045; HR 2.88, 95% CI 1.10–7.52, p= .031; HR 2.59, 95% CI 1.11–6.04, p= .028).Conclusions: Concurrent CRT is a well-tolerated treatment option with no additional toxicity compared to exclusive radiotherapy or sequential CRT. |
| قاعدة البيانات: | Supplemental Index |
| تدمد: | 03008916 20382529 |
|---|---|
| DOI: | 10.1177/0300891618765565 |